Literature DB >> 15732410

Hypertonic saline.

J E Smith1, M J Hall.   

Abstract

The optimal fluid for the resuscitation of critically ill and injured patients remains the subject of considerable controversy. Hypertonic crystalloid solutions such as hypertonic saline provide rapid volume expansion, have an acceptable safety profile, and are easy to store and transport. Recent meta-analyses suggest a trend toward increased survival in patients given hypertonic saline, and it has been suggested that they may have particular benefit in certain groups of patients such as hypovolaemic head injury patients. This short review examines the physiological and experimental evidence supporting the use of hypertonic saline in fluid resuscitation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15732410     DOI: 10.1136/jramc-150-04-03

Source DB:  PubMed          Journal:  J R Army Med Corps        ISSN: 0035-8665            Impact factor:   1.285


  4 in total

1.  Hypertonic saline increases gammadeltaT cell-mediated killing of activated neutrophils.

Authors:  Mark I Hirsh; Naoyuki Hashiguchi; Wolfgang G Junger
Journal:  Crit Care Med       Date:  2008-12       Impact factor: 7.598

2.  Effect of hypertonic saline on hypotension following induction of general anesthesia: A randomized controlled trial.

Authors:  Parviz Kashefi; Kamran Montazeri; Seyed Taghi Hashemi
Journal:  Adv Biomed Res       Date:  2014-09-04

3.  The Effect of Osmotherapy and Tight Control of Acidosis on Early Graft Function among Deceased-Donor Kidney Transplant Recipients: A Randomized Controlled Trial.

Authors:  F Etezadi; A H Najafi Abrandabadi; J Motaharinia; M Mojtahedzadeh; P Pourfakhr; M R Khajavi; S Gooran; R Shariat Moharari; S Dehghani
Journal:  Int J Organ Transplant Med       Date:  2017-02-01

4.  Effect of Hypertonic Saline 5% on Early Graft Function and Urinary Interleukin 18 and Neutrophil Gelatinase-Associated Lipocalin in Deceased-Donor Kidney Transplantation.

Authors:  Mojtaba Mojtahedzadeh; Farhad Etezadi; Gholamreza Pourmand; Amir Hossein Najafi Abrandabadi; Javad Motaharinia
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.